Strategic Focus Target late-stage development and rare neurodegenerative disorders with high unmet need, specifically TA-ERT for MPS IIIB, offering a clear niche for partnerships, licensing, and potential co-development deals with specialty biopharma and patient advocacy groups.

Clinical Leadership Recent key hires in clinical development leadership signal readiness for near-term regulatory strategy and pivotal trial execution, presenting opportunities for engagement with medical affairs, clinical development outsourcing, and investigator-led studies.

Funding Readiness Significant funding and a Nasdaq listing position Spruce as a credible partner for capital-efficient collaborations, joint ventures, or milestone-based partnerships with larger biopharma seeking to augment neurology portfolios.

Strategic Events Active participation in investor conferences and healthcare summits provides access to potential investors and strategic partners; coordinate outreach around upcoming conferences to accelerate partnering conversations and term-sheet opportunities.

Market Position Focused on a rare pediatric neurodegenerative indication with no FDA-approved therapies, presenting a compelling value proposition for specialty contract research organizations, patient-centric distribution channels, and payer discussions around transformative enzyme therapy.